Alzheimer's drug solanezumab could slow patients' decline

The first details of how a drug could slow the pace of brain decline for patients with early stage Alzheimer's disease have emerged.

Data from pharmaceutical company Eli Lilly suggests its solanezumab drug can cut the rate of the dementia's progression by about a third.

The results, presented to a US conference, are being met with cautious optimism.

A new trial is due to report next year and should provide definitive evidence.

Fergus Walsh reports.